Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063230 · ClinicalTrials.gov registry record · Phase 1
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02063230 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 32 participants.
The verdict
NCT02063230, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
Interventions
- DRUG Selumetinib 50mg
- DRUG Selumetinib 25mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02063230
The ClinicalTrials.gov registry entry for NCT02063230 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selumetinib 50mg is the first listed.
NCT02063230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02063230 about?
NCT02063230 is a clinical study titled "To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects". A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
What is the current status of trial NCT02063230?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2014-03. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02063230?
The interventions under investigation include: Selumetinib 50mg (DRUG), Selumetinib 25mg (DRUG).
Who is sponsoring clinical trial NCT02063230?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.